Published in Cell Death Differ on August 06, 2010
Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ (2011) 1.74
p53 Isoforms: An Intracellular Microprocessor? Genes Cancer (2011) 1.37
p53 Family and Cellular Stress Responses in Cancer. Front Oncol (2014) 1.33
Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther (2013) 1.27
p53 Family: Role of Protein Isoforms in Human Cancer. J Nucleic Acids (2011) 1.26
p53 isoform Δ113p53/Δ133p53 promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage. Cell Res (2015) 1.11
Diverse p63 and p73 isoforms regulate Δ133p53 expression through modulation of the internal TP53 promoter activity. Cell Death Differ (2011) 1.03
Drosophila p53 isoforms differentially regulate apoptosis and apoptosis-induced proliferation. Cell Death Differ (2012) 1.02
Def defines a conserved nucleolar pathway that leads p53 to proteasome-independent degradation. Cell Res (2013) 1.00
p63 the guardian of human reproduction. Cell Cycle (2012) 0.98
Influenza A viruses control expression of proviral human p53 isoforms p53β and Delta133p53α. J Virol (2012) 0.98
NRF2 and p53: Januses in cancer? Oncotarget (2012) 0.98
The p53 isoforms are differentially modified by Mdm2. Cell Cycle (2012) 0.94
Caspase-1 is a novel target of p63 in tumor suppression. Cell Death Dis (2013) 0.93
Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas. Front Oncol (2013) 0.86
The "Sharp" blade against HIF-mediated metastasis. Cell Cycle (2012) 0.86
p53 isoform Δ133p53 promotes efficiency of induced pluripotent stem cells and ensures genomic integrity during reprogramming. Sci Rep (2016) 0.86
Tissue-specific expression of p73 C-terminal isoforms in mice. Cell Cycle (2012) 0.84
p53 coordinates with Δ133p53 isoform to promote cell survival under low-level oxidative stress. J Mol Cell Biol (2015) 0.80
Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells. Oncotarget (2015) 0.80
The p53 isoform Δ133p53β promotes cancer stem cell potential. Stem Cell Reports (2015) 0.80
TP53 drives invasion through expression of its Δ133p53β variant. Elife (2016) 0.79
The significance of p53 isoform expression in serous ovarian cancer. Future Oncol (2012) 0.78
p53 protein isoforms: key regulators in the front line of pathogen infections? PLoS Pathog (2013) 0.78
Cancer-specific mutations in p53 induce the translation of Δ160p53 promoting tumorigenesis. EMBO Rep (2016) 0.77
Alpha-enolase is upregulated on the cell surface and responds to plasminogen activation in mice expressing a ∆133p53α mimic. PLoS One (2015) 0.77
Damage-inducible intragenic demethylation of the human TP53 tumor suppressor gene is associated with transcription from an alternative intronic promoter. Mol Carcinog (2015) 0.77
p53 isoforms change p53 paradigm. Mol Cell Oncol (2014) 0.76
2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells. Proc Natl Acad Sci U S A (2016) 0.76
Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness. Int J Mol Sci (2016) 0.75
A naturally occurring 4-bp deletion in the intron 4 of p53 creates a spectrum of novel p53 isoforms with anti-apoptosis function. Nucleic Acids Res (2014) 0.75
Evaluation and comparison of computational tools for RNA-seq isoform quantification. BMC Genomics (2017) 0.75
Post-translational regulation of p53 function through 20S proteasome-mediated cleavage. Cell Death Differ (2017) 0.75
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (1998) 17.91
p53 in health and disease. Nat Rev Mol Cell Biol (2007) 11.33
p53 isoforms can regulate p53 transcriptional activity. Genes Dev (2005) 6.76
The complexity of p53 stabilization and activation. Cell Death Differ (2006) 3.61
Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ (2006) 3.53
p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ (2006) 3.49
Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci (1992) 3.18
Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene (1993) 3.08
Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res (1994) 3.02
p63 and p73: roles in development and tumor formation. Mol Cancer Res (2004) 2.96
Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev (1994) 2.88
p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev (2009) 2.57
p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol (2009) 2.46
DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene (2002) 2.27
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J (2007) 2.07
Further characterisation of the p53 responsive element--identification of new candidate genes for trans-activation by p53. Oncogene (1997) 1.68
p53 and its isoforms in cancer. Br J Cancer (2007) 1.62
Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J Biol Chem (2004) 1.61
Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res (2008) 1.44
p53 and disease: when the guardian angel fails. Cell Death Differ (2006) 1.41
p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene (1998) 1.38
A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin Cancer Res (2006) 1.34
Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer (2007) 1.29
Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane. J Cell Biol (2002) 1.27
p53-dependent apoptosis or growth arrest induced by different forms of radiation in U2OS cells: p21WAF1/CIP1 repression in UV induced apoptosis. Oncogene (1999) 1.23
Transcriptional repression by the C-terminal domain of p53. Oncogene (1995) 1.20
p53: more research and more questions. Cell Death Differ (2006) 1.08
Expression of novel p53 isoforms in oral lichen planus. Oral Oncol (2007) 0.98
Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur J Cancer (2007) 0.94
Identification of a novel Bcl-2 promoter region that counteracts in a p53-dependent manner the inhibitory P2 region. Gene (2007) 0.92
Bromodeoxyuridine/DNA analysis of replication in CHO cells after exposure to UV light. Mutat Res (1993) 0.82
T antigen is bound to a host protein in SV40-transformed cells. Nature (1979) 17.78
Cancer. p53, guardian of the genome. Nature (1992) 16.36
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J (1990) 6.34
Regulation of the specific DNA binding function of p53. Cell (1992) 6.16
Negative regulation of viral enhancers in undifferentiated embryonic stem cells. Cell (1985) 5.88
p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A (1990) 5.43
Close amino acid sequence relationship between the new plasmid-mediated extended-spectrum beta-lactamase MEN-1 and chromosomally encoded enzymes of Klebsiella oxytoca. Biochim Biophys Acta (1992) 5.09
An immunoaffinity purification procedure for SV40 large T antigen. Virology (1985) 4.81
Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell (1993) 4.62
SUMO-1 modification activates the transcriptional response of p53. EMBO J (1999) 4.19
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene (1990) 3.89
Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol (1986) 3.72
p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ (2006) 3.49
SV40 large T shares an antigenic determinant with a cellular protein of molecular weight 68,000. Nature (1980) 3.44
Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci (1990) 3.35
p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature (1987) 3.34
The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res (1994) 3.28
An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods (1992) 3.23
High levels of p53 protein in UV-irradiated normal human skin. Oncogene (1993) 3.15
Using the polymerase chain reaction to modify expression plasmids for epitope mapping. Nucleic Acids Res (1989) 3.15
Epigenetic change in IGF2R is associated with fetal overgrowth after sheep embryo culture. Nat Genet (2001) 3.05
Two pathways for base excision repair in mammalian cells. J Biol Chem (1996) 3.01
Small peptides activate the latent sequence-specific DNA binding function of p53. Cell (1995) 2.96
Coronary artery bypass surgery: the relationship between inhospital mortality rate and surgical volume after controlling for clinical risk factors. Med Care (1991) 2.92
Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci U S A (1997) 2.90
Requirement for the replication protein SSB in human DNA excision repair. Nature (1991) 2.80
Nuclear protein with sequence homology to translation initiation factor eIF-4A. Nature (1988) 2.77
Use of monoclonal antibodies as probes of simian virus 40 T antigen ATPase activity. J Biol Chem (1981) 2.77
Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature (1991) 2.75
Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol (2000) 2.72
A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol (1991) 2.71
A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr Biol (1995) 2.57
An immunochemical investigation of SV40 T antigens. 1. Production properties and specificity of rabbit antibody to purified simian virus 40 large-T antigen. Virology (1978) 2.49
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene (1991) 2.42
p53 in tumour pathology: can we trust immunohistochemistry?--Revisited! J Pathol (1994) 2.41
Structure and function of SV40 large-T antigen. Philos Trans R Soc Lond B Biol Sci (1987) 2.37
An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene (2000) 2.36
The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis. Histopathology (1991) 2.32
p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene (1997) 2.31
A novel plasmid-mediated extended-spectrum beta-lactamase not derived from TEM- or SHV-type enzymes. J Antimicrob Chemother (1992) 2.28
Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc Natl Acad Sci U S A (1998) 2.28
Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep (2001) 2.27
Allosteric activation of latent p53 tetramers. Curr Biol (1994) 2.25
Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol (1997) 2.25
Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene (2001) 2.14
DbpA: a DEAD box protein specifically activated by 23s rRNA. EMBO J (1993) 2.04
Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature (1991) 1.99
Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene (1999) 1.98
Nuclear protein p68 is an RNA-dependent ATPase. EMBO J (1989) 1.98
p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet (1991) 1.95
Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene (1994) 1.94
A role for the human single-stranded DNA binding protein HSSB/RPA in an early stage of nucleotide excision repair. Nucleic Acids Res (1992) 1.91
Large and ongoing outbreak of haemolytic uraemic syndrome, Germany, May 2011. Euro Surveill (2011) 1.83
P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer (2005) 1.83
Characterization of human p53 antigens employing primate specific monoclonal antibodies. Virology (1983) 1.78
Origins of the prestalk-prespore pattern in Dictyostelium development. Cell (1989) 1.78
Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays (1995) 1.75
Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J Mol Biol (1995) 1.75
An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp Cell Res (1999) 1.74
Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ (2011) 1.74
Cryoprecipitate reversal of opsonic alpha2-surface binding glycoprotein deficiency in septic surgical and trauma patients. Science (1978) 1.73
Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp Cell Res (2001) 1.73
Cancer. A death in the life of p53. Nature (1993) 1.70
The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays (1993) 1.70
p68 RNA helicase: identification of a nucleolar form and cloning of related genes containing a conserved intron in yeasts. Mol Cell Biol (1991) 1.69
Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer (1990) 1.69
Isolation and analysis of the fission yeast gene encoding polymerase delta accessory protein PCNA. EMBO J (1992) 1.68
Molecular characterization of the hdm2-p53 interaction. J Mol Biol (1997) 1.64
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene (2012) 1.62
Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J Mol Biol (1992) 1.62
Update on the ongoing outbreak of haemolytic uraemic syndrome due to Shiga toxin-producing Escherichia coli (STEC) serotype O104, Germany, May 2011. Euro Surveill (2011) 1.58
Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci (1995) 1.57
Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet (1992) 1.53
Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci U S A (2000) 1.52
Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene (1995) 1.51
Opsonic alpha2 surface binding glycoprotein therapy during sepsis. Ann Surg (1978) 1.49
Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res (1993) 1.49
Ku selectively transfers between DNA molecules with homologous ends. J Biol Chem (1997) 1.46
Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol (1991) 1.46
The p53 response to ionising radiation in adult and developing murine tissues. Oncogene (1996) 1.46
APC expression in normal human tissues. J Pathol (1997) 1.44
The complex between simian virus 40 T antigen and a specific host protein. Proc R Soc Lond B Biol Sci (1980) 1.41
Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene (1991) 1.40
The effect of a surgery-specific cardiac output-guided haemodynamic algorithm on outcomes in patients undergoing pancreaticoduodenectomy in a high-volume centre: a retrospective comparative study. Anaesth Intensive Care (2017) 1.39
Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell (1992) 1.39
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer (1991) 1.39
Identification of novel mdm2 binding peptides by phage display. Oncogene (1996) 1.37
Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene (2008) 1.37
The p53 tumour suppressor gene. Br J Surg (1998) 1.37
Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene (1991) 1.36
Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ (2010) 1.35
C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances. Oncogene (2012) 1.35
Age-related changes in collagen gene expression in the muscles of mdx dystrophic and normal mice. Neuromuscul Disord (1994) 1.34
p53-dependent growth arrest following calcium phosphate-mediated transfection of murine fibroblasts. Oncogene (1995) 1.34
p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res (1993) 1.34
Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-ordinate DNA replication and repair. Oncogene (1997) 1.34
PCNA binding proteins in Drosophila melanogaster : the analysis of a conserved PCNA binding domain. Nucleic Acids Res (1998) 1.32
Loss of heterozygosity and mutational alterations of the p53 gene in skin tumours of interspecific hybrid mice. Oncogene (1991) 1.32
Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene (1999) 1.30